Can fast-growing Eliquis overtake J&J's Xarelto? Bristol's execs think so

Eliquis, a new-age anticoagulant that once dragged well behind analysts' expectations, has seriously picked up the pace lately, rocketing to the top of Bristol-Myers Squibb's ($BMY) sales charts. And company execs don't expect it to stop there. As CEO Giovanni Caforio put it on last week's Q4 conference call, its recent performance puts the company "well on our way" to passing by a pair of hefty competitors in Johnson & Johnson ($JNJ) and Bayer's Xarelto and Boehringer Ingelheim's Pradaxa. More from FiercePharmaMarketing

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.